Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1162]
News [2553]
Articles [160]
Editorials [8]
Conferences [104]
elearning [18]
FDA approves first biosimilar for the treatment of cancer
FDA approves first biosimilar for the treatment of cancer
Chronic cell death promotes liver cancer
Chronic cell death promotes liver cancer
ESMO 2017: Combined lenvatinib and pembrolizumab produces notable response rates in advanced renal carcinoma
ESMO 2017: Combined lenvatinib and pembrolizumab produces notable response rates in advanced renal carcinoma
ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer
ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer
ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer
ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer
Liver cancer patients can start with lower dose of chemotherapy and live just as long
Liver cancer patients can start with lower dose of chemotherapy and live just as long
ESMO 2017: Patients with high risk prostate cancer may benefit “equally” from two new treatments
ESMO 2017: Patients with high risk prostate cancer may benefit “equally” from two new treatments
The STING of death in T cells
The STING of death in T cells
Recurrence of prostate cancer could be reduced thanks to exciting new discovery
Recurrence of prostate cancer could be reduced thanks to exciting new discovery
European Commission approves pembrolizumab for treatment of advanced bladder cancers
European Commission approves pembrolizumab for treatment of advanced bladder cancers

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation